

Table S3. Tertile levels for each biomarker. Percentage of long-term users are shown within square brackets for each tertile, along with the corresponding proportions of primary and secondary responders.

Biomarker	Tertile 1 (ng/ml) [%total LTU (%PR/%SR)]	Tertile 2 (ng/ml) [%total LTU (%PR/%SR)]	Tertile 3 (ng/ml) [%total LTU (%PR/%SR)]	P-value
C1M	11.8 - 38.3 [91 (55/36)]	41.1–107.8 [45 (27/18)]	108.6–244.4 [20 (10/10)]	0.004
C3M	6.9–10.5 [82 (45/36)]	10.6–15.2 [45 (18/27)]	15.3–26.5 [30 (30/0)]	0.049
PRO-C3	2.9–5.4 [55 (18/36)]	5.4–7.2 [36 (27/9)]	7.5–16.4 [70 (50/20)]	0.302
C3M/PRO-C3^a	0.7–1.6 [82 (45/36)]	1.6–2.6 [45 (27/18)]	2.7 – 5.0 [30 (20/10)]	0.049
C4M	16.3–24.5 [82 (45/36)]	25.2–36.7 [36 (18/18)]	39.2–75.7 [40 (30/10)]	0.062
C4G	10.0–15.5 [55 (27/27)]	15.8–25.6 [45 (18/27)]	25.9–79.3 [60 (50/10)]	0.795
PRO-C4	115.6–181.5 [73 (45/27)]	182.0–260.4 [64 (36/27)]	266.8 – 522.0 [20 (10/10)]	0.037
C4M/C4G^a	0.5–1.3 [73 (55/18)]	1.4–2.0 [64 (27/36)]	2.0–4.8 [20 (10/10)]	0.037
PRO-C4/C4M ^a	4.1–6.6 [55% (27/27)]	6.7–7.7 [45 (27/18)]	7.7–12.9 [60 (40/20)]	0.795
PRO-C4/C4G ^a	2.6–7.6 [73 (55/18)]	8.4–14.5 [55 (27/27)]	14.9–37.0 [30 (10/20)]	0.146
C6Ma3	0.4–0.6 [82 (36/45)]	0.6–0.8 [36 (36/0)]	0.9–1.5 [40 (20/20)]	0.062
CPa9-HNE	121.5–231.7 [82 (45/36)]	235.6–362.3 [55 (36/18)]	369.5–557.2 [20 (10/10)]	0.018
CPa9-HNE/C4G ^a	2.8–10.9 [64 (36/27)]	11.6–18.5 [64 (36/27)]	18.9–46.1 [30 (20/10)]	0.210

Abbreviations: LTU, long-term users; PR, primary responders; SR, secondary responders.

^aBiomarker ratios with no concentration unit.